176 related articles for article (PubMed ID: 26492520)
1. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
Maurer MJ; Jais JP; Ghesquières H; Witzig TE; Hong F; Haioun C; Thompson CA; Thieblemont C; Micallef IN; Porrata LF; Ribrag V; Nowakowski GS; Casasnovas O; Bologna S; Morschhauser F; Morrison VA; Peterson BA; Macon WR; Copie-Bergman C; Feldman AL; Syrbu SI; Kurtin PJ; Gascoyne RD; Li H; Allmer C; Kahl BS; Ansell SM; Slager SL; Link BK; Salles G; Habermann TM; Tilly H; Cerhan JR
Am J Hematol; 2016 Feb; 91(2):179-84. PubMed ID: 26492520
[TBL] [Abstract][Full Text] [Related]
2. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ; Ghesquières H; Jais JP; Witzig TE; Haioun C; Thompson CA; Delarue R; Micallef IN; Peyrade F; Macon WR; Jo Molina T; Ketterer N; Syrbu SI; Fitoussi O; Kurtin PJ; Allmer C; Nicolas-Virelizier E; Slager SL; Habermann TM; Link BK; Salles G; Tilly H; Cerhan JR
J Clin Oncol; 2014 Apr; 32(10):1066-73. PubMed ID: 24550425
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma.
Novak AJ; Asmann YW; Maurer MJ; Wang C; Slager SL; Hodge LS; Manske M; Price-Troska T; Yang ZZ; Zimmermann MT; Nowakowski GS; Ansell SM; Witzig TE; McPhail E; Ketterling R; Feldman AL; Dogan A; Link BK; Habermann TM; Cerhan JR
Blood Cancer J; 2015 Aug; 5(8):e346. PubMed ID: 26314988
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study.
Kim YR; Kim SJ; Lee HS; Jeon S; Cho H; Chung H; Jang JE; Cheong JW; Min YH; Kim JS
Cancer Res Treat; 2022 Apr; 54(2):613-620. PubMed ID: 34352996
[TBL] [Abstract][Full Text] [Related]
6. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
Bairey O; Shacham-Abulafia A; Shpilberg O; Gurion R
Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
[TBL] [Abstract][Full Text] [Related]
7. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
Maurer MJ; Ellin F; Srour L; Jerkeman M; Bennani NN; Connors JM; Slack GW; Smedby KE; Ansell SM; Link BK; Cerhan JR; Relander T; Savage KJ; Feldman AL
J Clin Oncol; 2017 Dec; 35(36):4019-4026. PubMed ID: 29072976
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
Maurer MJ; Ghesquières H; Link BK; Jais JP; Habermann TM; Thompson CA; Haioun C; Allmer C; Johnston PB; Delarue R; Micallef IN; Peyrade F; Inwards DJ; Ketterer N; Farooq U; Fitoussi O; Macon WR; Molina TJ; Syrbu S; Feldman AL; Slager SL; Weiner GJ; Ansell SM; Cerhan JR; Salles GA; Witzig TE; Tilly H; Nowakowski GS
J Clin Oncol; 2018 Jun; 36(16):1603-1610. PubMed ID: 29672223
[TBL] [Abstract][Full Text] [Related]
9. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
10. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients.
Troppan KT; Melchardt T; Deutsch A; Schlick K; Stojakovic T; Bullock MD; Reitz D; Beham-Schmid C; Weiss L; Neureiter D; Wenzl K; Greil R; Neumeister P; Egle A; Pichler M
Eur J Haematol; 2015 Dec; 95(6):538-44. PubMed ID: 25677782
[TBL] [Abstract][Full Text] [Related]
11. The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.
Park JH; Yoon DH; Kim DY; Kim S; Seo S; Jeong Y; Lee SW; Park CS; Huh J; Suh C
Ann Hematol; 2014 Oct; 93(10):1755-64. PubMed ID: 25027115
[TBL] [Abstract][Full Text] [Related]
12. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
13. Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Ekwattanakit S; Khuhapinant A; Niparuck P; Chuncharunee S; Numbenjapon T; Prayongratana K; Kanitsap N; Wongkhantee S; Makruasri N; Wong P; Norasetthada L; Nawarawong W; Sirijerachai C; Chansung K; Suwanban T; Praditsuktavorn P; Intragumtornchai T;
Hematol Oncol; 2019 Dec; 37(5):578-585. PubMed ID: 31702065
[TBL] [Abstract][Full Text] [Related]
14. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
15. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Wang Y; Farooq U; Link BK; Larson MC; King RL; Maurer MJ; Allmer C; Hefazi M; Thompson CA; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Ansell SM; Cerhan JR; Nowakowski GS
J Clin Oncol; 2019 Jul; 37(21):1819-1827. PubMed ID: 31170029
[TBL] [Abstract][Full Text] [Related]
16. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG
Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
[TBL] [Abstract][Full Text] [Related]
19. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
[TBL] [Abstract][Full Text] [Related]
20. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
Maurer MJ; Bachy E; Ghesquières H; Ansell SM; Nowakowski GS; Thompson CA; Inwards DJ; Allmer C; Chassagne-Clément C; Nicolas-Virelizier E; Sebban C; Lebras L; Sarkozy C; Macon WR; Feldman AL; Syrbu SI; Traverse-Glehan A; Coiffier B; Slager SL; Weiner GJ; Witzig TE; Habermann TM; Salles G; Cerhan JR; Link BK
Am J Hematol; 2016 Nov; 91(11):1096-1101. PubMed ID: 27465588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
